Know the risk.Skip the animals.
Human-relevant toxicity data for regulatory filing generated in weeks, not years – with no animals harmed.
A future where everyone who needs treatments gets them. Because the science got the biology right from the start.
Over 90% of drugs fail in clinical trials that looked promising in animal models.
Companies lose decades and billions. Patients are tested with the wrong medicines.
THE HUMAN COST
Despite showing safety and efficacy in animals, clinical drug failures occur due to fundamental differences in biology. These failures ultimately delay patients receiving the medications they need.
The animal cost
Millions of animals — mice, rats, rabbits, dogs, primates — are bred and used in these tests every year. Most of this suffering is in vain.
THE FINANCIAL COST
Drug development now costs $2.6B on average and takes 10–15 years. Roughly half of this cost is from drug failures.
Built on 75–85% predictive accuracy
Validated against real human outcomes, not just historical animal-model correlation — across hepatic, renal and cardiac safety panels.
Zero
Zero animals tested.
100% human-relevant data.
Every compound we evaluate produces human-relevant data without sacrificing a single animal.
The FDA Modernization Act 2.0 removed the animal testing mandate in 2022. Azunic's platforms were designed around that shift from day one.
Built for every stage of drug development
Computational Assessment
AI-driven QSAR and PBK models trained on human data to predict ADMET profiles before any lab work begins.
QSAR ensemble evaluates compound structures against human clinical outcomes. PBK simulation predicts dose-response in human organ compartments.
Biological Validation
Advanced 3D human tissue culture systems are used to determine the toxicity risks of new drug candidates.
Our hepatic, renal, cardiac, intestinal, neural, and lung organoids are derived from biobanked human iPSC under full ethical consent.
Regulatory Package
Azunic doesn’t stop at the data. We coordinate your regulatory submission for IND/CTN, translating our findings into the package regulatory reviewers expect.
Complete regulatory-ready submissions aligned with FDA Modernization Act 2.0, ICH M7/S7A/S7B, and OECD Test Guidelines.
Rapid Screening
High-throughput compound triage in weeks. Kill or advance candidates before investing in full development.
From SMILES input to go/no-go in under 3 weeks. Tiered screening layers in silico flagging with targeted organoid confirmation.
Safety Deep-Dive
Mechanistic toxicology studies on target organs: liver, kidney, cardiac, CNS.
Multi-organ mechanistic study maps toxicity thresholds, reversibility, and pathway mechanisms for IND filing.
Regulatory Submission
Azunic handles IND/CTN submission coordination end to end, so your team can move from tox results to filing without juggling vendors or reformatting data.
Azunic handles IND/CTN submission coordination end to end, so your team can move from tox results to filing without juggling vendors or reformatting data.
The science is ready.
The regulators agree.
The FDA Modernization Act 2.0 explicitly enables non-animal testing methods. Azunic's platform defines a five-step pipeline that focuses on successful regulatory review.
12–16 weeks
Compressing what used to take years of animal studies into a fraction of the timeline.
Ready to leave animal testing behind?
Speak with our scientists. Get an assessment of your compound against our NAM platform.